|
|
Article: Clinic Roundup.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o ImClone Systems Inc., of New York, opened patient enrollment in the first of its Phase II trials of IMC-1121B, a monoclonal antibody targeted to the vascular endothelial growth factor receptor-2 (VEGFR-2). The study is expected to involve 36 patients with metastatic renal-cell carcinoma whose disease has progressed during therapy with an approved VEGFR-2 tyrosine kinase inhibitor or who have developed intolerance to those agents. IMC-1121B will be administered every two weeks by intravenous infusion. ImClone expects to begin additional studies over the next several months in various tumor types.
o MedImmune Inc., a Gaithersburg, Md., unit of AstraZeneca plc, ...